Boardroom Alpha
10-K primary document
APRE · Annual Report (Form 10-K) · Filed March 16, 2026

Aprea Therapeutics Inc10-K exhibit

apre-20251231xex10d6.htm

Exhibit 10.6

Aprea Therapeutics, Inc.

2019 Equity Incentive Plan 

Restricted Stock Unit Award Notice

<Awardee Name>

You have been awarded a restricted stock unit award with respect to shares of common stock of Aprea Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to the terms and conditions of the Aprea Therapeutics, Inc. 2019 Equity Incentive Plan (the “Plan”) and the Restricted Stock Unit Award Agreement (together with this Award Notice, the “Agreement”). Copies of the Plan and the Restricted Stock Unit Award Agreement are attached hereto. Capitalized terms not defined herein shall have the meanings specified in the Plan or the Agreement.

Restricted Stock Units:

  ​

You have been awarded a restricted stock unit award with respect to shares of Common Stock, par value $0.001 per share (the “Common Stock”) as follows, subject to adjustment as provided in the Plan.

RSUs Awarded

xxxx

Grant Date:

  ​

<Date of Award>

Vesting Commencement Date:

<Vesting Commencement Date>

Vesting Schedule:

  ​

Except as otherwise provided in the Plan, the Agreement or any other agreement between the Company or any of its Subsidiaries and you, the Award shall vest in three (3) equal installments on each of the first, second and third anniversaries of the Vesting Commencement Date (each such date, a “Vesting Date”) if, and only if, you are, and have been, continuously (except for any absence for vacation, leave, etc. in accordance with the Company’s or its Subsidiaries’ policies): (i) employed by the Company or any of its Subsidiaries; (ii) serving as a Non-Employee Director; or (iii) providing services to the Company or any of its Subsidiaries as an advisor or consultant, in each case, from the date of this Agreement through and including the applicable Vesting Date.

APREA THERAPEUTICS, INC.

By:

Name: Oren Gilad. Ph.D.

Title: President and Chief Executive Officer


Acknowledgment, Acceptance and Agreement:

By signing below and returning this Award Notice to Aprea Therapeutics, Inc., I hereby acknowledge receipt of the Agreement and the Plan, accept the Award granted to me and agree to be bound by the terms and conditions of this Award Notice, the Agreement and the Plan.

____________________________________

Holder


Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.

Full disclaimer